Senthil Lingaratnam
Senthil Lingaratnam
Unknown affiliation
Verified email at
Cited by
Cited by
Use of empiric antimicrobial therapy in neutropenic fever
CS Tam, M O'Reilly, D Andresen, S Lingaratnam, A Kelly, K Burbury, ...
Internal medicine journal 41 (1b), 90-101, 2011
Use of antibacterial prophylaxis for patients with neutropenia
MA Slavin, S Lingaratnam, L Mileshkin, DL Booth, MJ Cain, DS Ritchie, ...
Internal medicine journal 41 (1b), 102-109, 2011
Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs
K Thursky, S Lingaratnam, J Jayarajan, GM Haeusler, B Teh, M Tew, ...
BMJ open quality 7 (3), e000355, 2018
Use of risk stratification to guide ambulatory management of neutropenic fever
LJ Worth, S Lingaratnam, A Taylor, AM Hayward, S Morrissey, J Cooney, ...
Internal medicine journal 41 (1b), 82-89, 2011
Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011
S Lingaratnam, MA Slavin, B Koczwara, JF Seymour, J Szer, C Underhill, ...
Internal medicine journal 41 (1b), 75-81, 2011
Epidemiology of invasive fungal disease in lymphoproliferative disorders
JC Teng, MA Slavin, BW Teh, SM Lingaratnam, MR Ananda-Rajah, ...
Haematologica 100 (11), e462, 2015
Developing a performance data suite to facilitate lean improvement in a chemotherapy day unit
S Lingaratnam, D Murray, A Carle, SW Kirsa, R Paterson, D Rischin
Journal of Oncology Practice 9 (4), e115-e121, 2013
A ustralian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel
M Alexander, J King, A Bajel, C Doecke, P Fox, S Lingaratnam, JD Mellor, ...
Internal medicine journal 44 (10), 1018-1026, 2014
Late‐onset Pneumocystis jirovecii pneumonia post–fludarabine, cyclophosphamide and rituximab: implications for prophylaxis
GM Haeusler, MA Slavin, JF Seymour, S Lingaratnam, BW Teh, CS Tam, ...
European journal of haematology 91 (2), 157-163, 2013
The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset
S Lingaratnam, KA Thursky, MA Slavin, SW Kirsa, CA Bennett, LJ Worth
Internal medicine journal 41 (1b), 121-129, 2011
An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009
S Lingaratnam, MA Slavin, L Mileshkin, B Solomon, K Burbury, ...
Internal medicine journal 41 (1b), 110-120, 2011
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment
S Lingaratnam, LJ Worth, MA Slavin, CA Bennett, SW Kirsa, JF Seymour, ...
Australian Health Review 35 (4), 491-500, 2011
Fluoroquinolone prophylaxis: a word of caution
S Lingaratnam, KA Thursky, MA Slavin
Leukemia & Lymphoma 52 (1), 5-6, 2011
A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies
S Maleki, M Alexander, T Fua, C Liu, D Rischin, S Lingaratnam
Journal of Oncology Pharmacy Practice 25 (1), 130-139, 2019
Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: Clinical significance of quantitative polymerase chain reaction
BW Teh, FA Azzato, SM Lingaratnam, KA Thursky, MA Slavin, LJ Worth
Sabouraudia 52 (4), 427-432, 2014
A controlled before and after study to evaluate a patient and health professional partnership model towards effective medication reconciliation
S Lingaratnam, S Aranda, T Pearce, S Kirsa
Journal of Oncology Pharmacy Practice 19 (1), 48-56, 2013
Thromboprophylaxis among A ustralasian colorectal surgeons
P Smart, K Burbury, S Lingaratnam, AC Lynch, J Mackay, A Heriot
ANZ Journal of Surgery 83 (9), 646-650, 2013
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis
SM Lingaratnam, MA Slavin, KA Thursky, BW Teh, GM Haeusler, ...
Leukemia & Lymphoma 56 (1), 157-162, 2015
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital
M Alexander, KC Teoh, S Lingaratnam, S Kirsa, JD Mellor
Asia‐Pacific Journal of Clinical Oncology 9 (2), 169-175, 2013
A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel
M Alexander, J King, S Lingaratnam, J Byrne, K Macmillan, A Mollo, ...
Journal of Oncology Pharmacy Practice 22 (2), 219-227, 2016
The system can't perform the operation now. Try again later.
Articles 1–20